Detalles de la búsqueda
1.
A novel economic framework to assess the cost-effectiveness of bone-forming agents in the prevention of fractures in patients with osteoporosis.
Osteoporos Int
; 32(7): 1301-1311, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-33411005
2.
Cost effectiveness of romosozumab versus teriparatide for severe postmenopausal osteoporosis in Japan.
Osteoporos Int
; 32(10): 2011-2021, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-33772328
3.
The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus.
Diabet Med
; 32(7): 890-8, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-25817050
4.
Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective.
BMC Health Serv Res
; 15: 496, 2015 Nov 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-26541516
5.
Determinants of Increasing the Likelihood for a Positive Drug Reimbursement Recommendation in Scotland.
Value Health
; 17(7): A325, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-27200539
6.
The Impact of Long-Term Clinical Evidence on Cost-Effectiveness of Exenatide Once Weekly (Bydureon®) Versus Insulin Glargine for Patients With Type 2 Diabetes Mellitus (T2dm) From A Uk Nhs Perspective.
Value Health
; 17(7): A343, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-27200638
7.
Dapagliflozin (Forxiga®) Versus Glipizide As Add-On Therapies In Type 2 Diabetes Mellitus (T2dm); An Update of The Cost-Effectiveness Based On Long-Term Clinical Evidence From Uk Nhs Perspective.
Value Health
; 17(7): A343, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-27200640
8.
Economic Assessment of Delaying Insulin Treatment Through The Use of Newer Anti-Diabetic Agents, Dapagliflozin (Forxiga®) And Exenatide (Bydureon®), Both As Add-On To Metformin; A Cost-Effectiveness Analysis From A Uk Nhs Perspective.
Value Health
; 17(7): A344-5, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-27200644
9.
The Cost-Effectiveness of Dapagliflozin In Combination With Insulin for the Treatment of Type 2 Diabetes Mellitus (T2dm) In Spain.
Value Health
; 17(7): A350, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-27200677
10.
Factors Influencing Dutch Drug Reimbursement Recommendations; A Database Analysis.
Value Health
; 17(7): A441, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-27201185
11.
Cost-Effectiveness of Dapagliflozin Versus Dpp-4 Inhibitors as Monotherapy in the Treatment of Type 2 Diabetes Mellitus From A Uk Health Care Perspective.
Value Health
; 17(7): A347, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-27200659
12.
Cost-Effectiveness of Dapagliflozin Compared To Dpp-4 Inhibitors as Triple Therapy In Combination With Metformin and A Sulphonylurea In The Treatment Of Type 2 Diabetes Mellitus From A Uk Health Care Perspective.
Value Health
; 17(7): A347, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-27200660
13.
Cost-Effectiveness of Saxagliptin Compared To Glp-1 Analogues As An Add-On To Insulin in the Treatment of Type 2 Diabetes Mellitus From A Uk Health Care Perspective.
Value Health
; 17(7): A347, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-27200661
14.
A Comparison of Factors Influencing Reimbursement and Coverage Decisions in Scotland (Smc), The Netherlands (Nzi) and Germany (G-Ba).
Value Health
; 17(7): A430, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-27201119
15.
Using health economic models to help guide healthcare decisions.
Curr Med Res Opin
; 32(2): 205-6, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26473453
16.
Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective.
J Med Econ
; 19(12): 1127-1134, 2016 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-27310712
17.
Methods applied in cost-effectiveness models for treatment strategies in type 2 diabetes mellitus and their use in Health Technology Assessments: a systematic review of the literature from 2008 to 2013.
Curr Med Res Opin
; 32(2): 207-18, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26473650
Resultados
1 -
17
de 17
1
Próxima >
>>